The role of allogeneic HSCT after CAR T cells for acute lymphoblastic leukemia
Crossref DOI link: https://doi.org/10.1038/s41409-019-0604-3
Published Online: 2019-08-20
Published Print: 2019-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Jacoby, Elad
Text and Data Mining valid from 2019-08-01
Version of Record valid from 2019-08-01
Article History
First Online: 20 August 2019
Compliance with ethical standards
:
: The author has received lecture fees from Novartis, Israel, and received grant support from the Dotan Center for Hematologic Malignancies.